title: Controversies in Breast Cancer Screening Strategies.
abstract: A panel discussion on controversies in breast cancer screening held recently at the NCCN 21st Annual Conference included only a few controversies. Representatives of the U.S. Preventive Services Task Force, American Cancer Society, and NCCN disagreed primarily on 2 main areas: when to start screening (ages 40, 45, or 50 years) and frequency of screening (annual vs biennial). Panelists from these organizations presented the rationales for their respective recommendations.
authors.affiliation: Presented by Therese Bevers, MD, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Chair of the NCCN Guidelines for Breast Cancer Screening and Diagnosis; Kirsten Bibbins-Domingo, PhD, MD, MAS, University of California, San Francisco, San Francisco, California, and Chair of the U.S. Preventive Services Task Force; and Kevin C. Oeffinger, MD, Memorial Sloan Kettering Cancer Center, New York, New York, and Chair of the American Cancer Society Breast Cancer Screening Guideline Panel; facilitated by Mary Lou Smith, JD, MBA, Research Advocacy Network, Naperville, Illinois.
authors.forename: Therese
authors.initials: T
authors.lastname: Bevers
authors.affiliation: Presented by Therese Bevers, MD, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Chair of the NCCN Guidelines for Breast Cancer Screening and Diagnosis; Kirsten Bibbins-Domingo, PhD, MD, MAS, University of California, San Francisco, San Francisco, California, and Chair of the U.S. Preventive Services Task Force; and Kevin C. Oeffinger, MD, Memorial Sloan Kettering Cancer Center, New York, New York, and Chair of the American Cancer Society Breast Cancer Screening Guideline Panel; facilitated by Mary Lou Smith, JD, MBA, Research Advocacy Network, Naperville, Illinois.
authors.forename: Kirsten
authors.initials: K
authors.lastname: Bibbins-Domingo
authors.affiliation: Presented by Therese Bevers, MD, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Chair of the NCCN Guidelines for Breast Cancer Screening and Diagnosis; Kirsten Bibbins-Domingo, PhD, MD, MAS, University of California, San Francisco, San Francisco, California, and Chair of the U.S. Preventive Services Task Force; and Kevin C. Oeffinger, MD, Memorial Sloan Kettering Cancer Center, New York, New York, and Chair of the American Cancer Society Breast Cancer Screening Guideline Panel; facilitated by Mary Lou Smith, JD, MBA, Research Advocacy Network, Naperville, Illinois.
authors.forename: Kevin C
authors.initials: KC
authors.lastname: Oeffinger
authors.affiliation: Presented by Therese Bevers, MD, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Chair of the NCCN Guidelines for Breast Cancer Screening and Diagnosis; Kirsten Bibbins-Domingo, PhD, MD, MAS, University of California, San Francisco, San Francisco, California, and Chair of the U.S. Preventive Services Task Force; and Kevin C. Oeffinger, MD, Memorial Sloan Kettering Cancer Center, New York, New York, and Chair of the American Cancer Society Breast Cancer Screening Guideline Panel; facilitated by Mary Lou Smith, JD, MBA, Research Advocacy Network, Naperville, Illinois.
authors.forename: Mary Lou
authors.initials: ML
authors.lastname: Smith
mesh_terms: D001943:Breast Neoplasms / Q000175:diagnosis*; D055088:Early Detection of Cancer; D005260:Female; D006801:Humans; D008403:Mass Screening / Q000379:methods*; D008875:Middle Aged